685 related articles for article (PubMed ID: 15489556)
21. [Combined use of ondansetron and other anti-emetics to control cisplatin-induced nausea and vomiting].
Zeng WY
Zhonghua Zhong Liu Za Zhi; 1993 Mar; 15(2):118-21. PubMed ID: 8223120
[TBL] [Abstract][Full Text] [Related]
22. Prevention of nausea and vomiting (N&V) in cancer patients receiving high-dose cisplatin. Assessment of the potential antiemetic activity of transdermal fentanyl (TTS-F) compared to standard antiemetic treatment in acute and delayed N&V: first clinical report.
Mantovani G; Curreli L; Macciò A; Massa E; Massa D; Mulas C; Succu G; Contu P
Anticancer Res; 1999; 19(4C):3495-502. PubMed ID: 10629642
[TBL] [Abstract][Full Text] [Related]
23. Prevention of chemotherapy-induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents.
Bruntsch U; Drechsler S; Eggert J; Gosse H; Ukena D; Imhoff W; Faerber L
Semin Oncol; 1994 Oct; 21(5 Suppl 9):7-11. PubMed ID: 9113120
[TBL] [Abstract][Full Text] [Related]
24. Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Gebbia V; Testa A; Cannata G; Gebbia N
Anticancer Drugs; 1996 Sep; 7(7):734-7. PubMed ID: 8949983
[TBL] [Abstract][Full Text] [Related]
25. Ondansetron plus dexamethasone compared to the 'standard' metoclopramide combination.
Roila F
Oncology; 1993; 50(3):163-7. PubMed ID: 8459986
[TBL] [Abstract][Full Text] [Related]
26. Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial.
Shinkai T; Saijo N; Eguchi K; Sasaki Y; Tamura T; Tominaga K; Sakurai M; Sano T; Taito H; Takahashi H
Jpn J Clin Oncol; 1986 Sep; 16(3):279-87. PubMed ID: 3534348
[TBL] [Abstract][Full Text] [Related]
27. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Levitt M; Warr D; Yelle L; Rayner HL; Lofters WS; Perrault DJ; Wilson KS; Latreille J; Potvin M; Warner E
N Engl J Med; 1993 Apr; 328(15):1081-4. PubMed ID: 8455665
[TBL] [Abstract][Full Text] [Related]
28. [Examination on efficacy and safety of concurrent use of ondansetron hydrochloride and steroid in lung cancer patients on cisplatin].
Horichi N; Taguchi T; Furue H; Ikeda M; Tsukakoshi S
Gan To Kagaku Ryoho; 2001 Jul; 28(7):953-60. PubMed ID: 11478144
[TBL] [Abstract][Full Text] [Related]
29. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo.
Gandara DR; Harvey WH; Monaghan GG; Perez EA; Stokes C; Bryson JC; Finn AL; Hesketh PJ
Semin Oncol; 1992 Aug; 19(4 Suppl 10):67-71. PubMed ID: 1387253
[TBL] [Abstract][Full Text] [Related]
30. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.
Olver I; Paska W; Depierre A; Seitz JF; Stewart DJ; Goedhals L; McQuade B; McRae J; Wilkinson JR
Ann Oncol; 1996 Nov; 7(9):945-52. PubMed ID: 9006746
[TBL] [Abstract][Full Text] [Related]
31. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.
Cunningham D; Dicato M; Verweij J; Crombez R; de Mulder P; du Bois A; Stewart A; Smyth J; Selby P; van Straelen D; Parideans R; McQuade B; McRae J
Ann Oncol; 1996 Mar; 7(3):277-82. PubMed ID: 8740792
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
33. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of tropisetron and dexamethasone in the prevention of cisplatin-induced emesis.
Voravud N; Suwanrusmee H
J Med Assoc Thai; 2000 Jun; 83(6):668-75. PubMed ID: 10932495
[TBL] [Abstract][Full Text] [Related]
35. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer. Italian Group for Antiemetic Research.
Support Care Cancer; 1994 May; 2(3):167-70. PubMed ID: 8032702
[TBL] [Abstract][Full Text] [Related]
36. Progress in the control of acute and delayed emesis induced by cisplatin.
Gandara DR
Eur J Cancer; 1991; 27 Suppl 1():S9-11; discussion S22. PubMed ID: 1831633
[TBL] [Abstract][Full Text] [Related]
37. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
38. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.
Plosker GL; Milne RJ
Pharmacoeconomics; 1992 Oct; 2(4):285-304. PubMed ID: 10147044
[TBL] [Abstract][Full Text] [Related]
39. [A randomized controlled trial of acute and delayed cisplatin-induced emesis with metoclopramide, dexamethasone and prochlorperazine].
Nino S; Umehara H; Inoue I; Tamura T; Sasaki Y; Sakurai M; Shinkai T; Eguchi K; Saijo N; Suemasu K
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2881-4. PubMed ID: 3310905
[TBL] [Abstract][Full Text] [Related]
40. Intravenous ondansetron plus intravenous dexamethasone with different ondansetron dosing schedules during multiple cycles of cisplatin-based chemotherapy.
Chen PT; Liaw CC
Chang Gung Med J; 2008; 31(2):167-74. PubMed ID: 18567417
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
